Open Access
Access granted
Subscription or Fee Access
Vol 27, No 4 (2016)
- Year: 2016
- Articles: 24
- URL: https://journals.eco-vector.com/0236-3054/issue/view/5958
Articles
2-6
EXPERIENCE IN RECORDING UNDESIRABLE SIDE EFFECTS FROM ANTIEPILEPTIC DRUGS IN THE KRASNOYARSK MEDICAL UNIVERSITY CLINIC
Abstract
The paper describes some experience in recording adverse reactions to antiepileptic drugs. To train physicians in pharmacovigilance, to include information on undesirable side effects from the drugs into the structure of a clinical diagnosis, and to comply with the current pharmacovigilance legislative requirements increase the detection rates of side effects from the drugs.
Vrach. 2016;27(4):6-8
6-8
DIAGNOSIS AND TREATMENT OF ACUTE BACK PAIN
Abstract
Vertebrogenic pains are a heterogeneous group of abnormalities, which encompasses musculoskeletal dysfunction and nerve root compression. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated to ease pain syndrome and local inflammation. NSAIDs have also proven to be effective when topically applied.
Vrach. 2016;27(4):9-13
9-13
13-16
16-20
KOKARNIT: AN ANALGESIC POTENTIAL IN THE TREATMENT OF DIABETIC POLYNEUROPATHY
Abstract
The medicine Kokarnit, a lyophilysate to prepare a solution for intramuscular injection (World Medicine Ltd, United Kingdom), is a combination of a few active ingredients (triphosadenine dinatrium trihydrate, cocarboxylase, cyanocobalamin, nicotinamide). Kokarnit not only provides metabolic effects and synergism of analgesic action in combination with nonsteroidal anti-inflammatory drugs, but also has an analgesic potential, this is important to improve quality of life in patients with polyneuropathies accompanied by pain syndrome that is untreated with pharmacotherapy.
Vrach. 2016;27(4):20-26
20-26
PROBIOTICS IN SURGERY
Abstract
The paper gives data on potential benefits to a patient and a surgeon from introducing probiotics into clinical practice to treat surgical diseases. Numerous studies have demonstrated a lower risk for surgical site infections, anastomotic incompetence, and pulmonary and urologic complications when the probiotics are used. An attempt has been made to summarize available information about this and to give specific recommendations for the choice of a probiotic, its dosage, and the frequency and duration of its use in surgical patients.
Vrach. 2016;27(4):27-32
27-32
FIBROGENESIS AS AN OBJECT OF PHARMACOLOGICAL REGULATION: ALTERNATIVE ABILITIES OF SLOW-RELEASE CALCIUM CHANNEL BLOCKERS
Abstract
The paper discusses whether slow-release calcium channel blockers (SCCBs) may be used to regulate the processes of connective tissue formation. The main pathogenetic components of fibrogenesis, which determine the expediency of the administration and efficiency of SCCBs, are defined. The authors give the results of their own studies of the antifibrotic effect of verapamil.
Vrach. 2016;27(4):33-35
33-35
35-39
39-41
41-43
43-44
THERAPY IN WOMEN WITH HYPERTENSION AND ESTROGEN DEFICIENCY IN THE LATE FERTILE PERIOD
Abstract
The impact of therapy with an angiotensin-converting enzyme inhibitor (Lisinopril) in combination with a third-generation calcium channel blocker (amlodipine) on blood pressure level, left cardiac remodeling, and silent myocardial ischemia in 133 antihypertensive women with estrogen deficiency in the late fertile period in relation to the genotype of the estrogen receptor gene.
Vrach. 2016;27(4):45-49
45-49
49-53
TIME COURSE OF CHANGES IN THE LEVELS OF HORMONES IN OBESE WOMEN LOSING WEIGHT
Abstract
Obesity is an urgent problem of modern medicine not only because of a steep rise in its incidence. Most obese people suffer from depression and/or have other psychological problems. Understanding the mechanisms of bidirectional risks between obesity and common mental disorders is necessary for the effective treatment and prevention of these diseases.
Vrach. 2016;27(4):53-55
53-55
55-58
PIRIBEDIL IN THE TREATMENT OF PATIENTS WITH CHRONIC BRAIN ISCHEMIA AND COGNITIVE DISORDERS
Abstract
Chronic brain ischemia (CBI) is manifested by a set of neuropsychological and neurological symptoms. Cognitive impairments detected in patients with CBI largely determine their state. Just at the earliest stages of CBI, there is abnormal metabolism of mediators, primarily dopaminergic, cholinergic, and glutamatergic ones. One of the drugs that modulate the dopaminergic system is Piribedil (Pronoran) that belongs to nonergolinic dopamine receptor agonists and stimulates D2 and D3 receptors. Numerous trials confirm its safety and efficacy in affecting cognitive, psychoemotional, and motor disorders in patients with CBI.
Vrach. 2016;27(4):58-63
58-63
63-68
68-71
71-75
EVALUATION OF THE EFFICIENCY OF USING NOOTROPICS TO TREAT COGNITIVE DYSFUNCTIONS IN CHILDREN
Abstract
The paper gives the results of a comparative evaluation of using nootropics, such as piracetam and choline alfoscerate (gliatilin). Gliatilin has been ascertained to exert a more pronounced positive effect than nootropil in correcting cognitive functions and astheno-autonomic disorders.
Vrach. 2016;27(4):75-78
75-78
78-81
82-85
85-88